NCT05835934已完成1 期
A Phase I Clinical Study on Absorption, Metabolism, and Excretion of [14C]HSK21542 in Healthy Adult Male Chinese Subjects - Mass Balance and Biotransformation of [14C]HSK21542 in Human.
Haisco Pharmaceutical Group Co., Ltd.1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2021年6月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Mass balance
研究概览
简要总结
This is a single-center, nonrandomized, and open design study to investigate the pharmacokinetics, mass balance, metabolism and excretion of HSK21542 in healthy male subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy Chinese males, aged 18-45 years old (inclusive);
- •Body weight ≥ 50.0 kg and body mass index (BMI) between 19.0-26.0 kg/m2 (inclusive);
- •Vital signs: blood pressure between 90-139/60-89 mmHg; heart rate or pulse between 60-99 beats/min;
- •Subjects judged by the investigator based on past medical history, comprehensive physical examination, vital signs examination, and other prescribed tests;
- •Subjects who voluntarily sign the informed consent form (ICF), able to communicate with the investigator and to complete all trial procedures as per the protocol.
排除标准
- •Clinically significant abnormal results for comprehensive physical examination, vital signs, routine laboratory tests [blood routine, blood biochemistry, coagulation routine, urine routine, stool routine + occult blood, thyroid function, visual acuity and ophthalmic examination (slit lamp, introcular pressure, and fundoscopy), 12-lead electrocardiogram (ECG), chest X-ray (anteriorposterior), and abdominal B-ultrasound (liver, gallbladder, pancreas, spleen, and kidney);
- •Positive for hepatitis B surface antigen or E antigen, hepatitis C antibody, HIV antibody, or Treponema pallidum antibodies;
- •Medication history:
- •Use of any Western medicine or Chinese patent medicine (including prescription drug, over-the-counter drug, health care product, or live attenuated influenza vaccine) within 14 days prior to screening;
- •Participation in any clinical trial and interference with other investigational drug or medical device within 3 month prior to screening;
- •Medical history and surgical history:
- •History of serious clinical diseases or diseases/conditions that the investigator believes may affect the study results, including but not limited to the history of diseases in the motor system, nervous system, endocrine system, circulatory system, respiratory system, digestive system, urinary system, and reproductive system;
- •Past history of organic heart disease, heart failure, myocardial infarction, angina, unexplained arrhythmia, torsades de pointes, ventricular tachycardia, long QT syndrome or symptoms and familial history of long QT syndrome (indicated by genetic evidence or sudden death of a close relative at a young age due to cardiac causes);
- •Have undergone major surgery within 6 months prior to screening or with incomplete healing of the surgical incision; major surgery includes, but is not limited to, any surgery with significant risk of bleeding, prolonged general anesthesia, or incisional biopsy or obvious traumatic injury (excluding cured appendicitis surgery or rectal prolapse surgery);
- •Severe allergic constitution, including known allergy to any excipient of this investigational product (Glacial acetic acid, sodium acetate, water for injection), two or more drugs and food components, or with special dietary requirements and thus unable to follow a standardized diet;
- •Living habits:
- •Long-term excessive consumption (more than 8 cups a day, 1 cup =250mL) of tea, grapefruit, coffee, drinks containing caffeine or grapefruit;
- •Subjects with a history of alcohol abuse in the three months prior to screening, with an average daily intake of more than 15 g of alcohol (15 g of alcohol is equivalent to 360 mL of beer or 150 mL of wine or 50 mL of liquor containing 40% alcohol), or with a positive alcohol breath test (test value greater than 20 mg/100 mL);
- •Subjects who smoked more than 5 cigarettes a day or habitually used nicotine-containing products in the 3 months before the screening period and could not quit during the test period;
- •Drug abuse or dependence, urine screening positive for drug abuse;
- •Workers engaged in work requiring prolonged exposure to radioactivity; Or had significant radiation exposure (≥2 chest/abdominal CT scans, or ≥3 other types of X-rays) within 1 year or participated in the radiopharma labeling test prior to the test;
- •Those who had a birth plan during the study period and within 1 year after completion of the study, or who did not agree that the subject and his or her spouse should take strict contraceptive measures (condoms, contraceptive sponges, contraceptive gels, contraceptive membranes, intrauterine devices, oral or injectable contraceptives, subcutaneous implants, etc.) during the study period and within 1 year after completion of the study;
- •Volunteers judged by the investigator to be unsuitable for participating in this trial for any reason.
研究组 & 干预措施
Arms
Experimental
2 μg/0.212 μCi/kg [14C]HSK21542
干预措施: [14C]HSK21542 (Drug)
结局指标
主要结局
Mass balance
时间窗: From the start of administration to 240 h after administration
Percentage of cumulative drug excretion of \[14C\]HSK21542 on biological pecimens(urine and faeces) accounting for total radiation drug dose.
次要结局
- Area under the concentration-time curve (AUC0-t, AUC0-∞)(From the start of administration to 240 h after administration)
- Peak concentration (Cmax)(From the start of administration to 240 h after administration)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Mass Balance Study of [14C]HSK31858 in Healthy Adult Male Chinese Subjects.HealthyNCT06569784Xizang Haisco Pharmaceutical Co., Ltd6
进行中（未招募）
1 期
Pharmacokinetics, Mass Balance, and Metabolism of [14C]HSK31679 in Healthy Adult Male Volunteers.HealthyNCT06258746Xizang Haisco Pharmaceutical Co., Ltd6
已完成
1 期
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB TreatmentTuberculosis, PulmonaryBacterial Infections RespiratoryLung DiseasesMycobacterium InfectionsTuberculosisNCT04874948Michael Hoelscher4
已完成
1 期
A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)Healthy VolunteersNCT05511558Athira Pharma8
已完成
1 期
The Absorption, Metabolism and Excretion of [14C]CM082 in HumanAdvanced Solid TumorNCT04434326AnewPharma4